Law firms investigate ADMA Biologics for potential securities violations following unexpected auditor resignation and stock decline.

Bragar Eagel & Squire, P.C. and Bleichmar Fonti & Auld LLP are investigating ADMA Biologics, Inc. for potential violations of federal securities laws after the unexpected resignation of the company's auditor, CohnReznick LLP, on October 9, 2024. This event caused a notable decline in stock value. Both law firms are reaching out to affected shareholders for potential legal claims and representation options.

October 16, 2024
7 Articles

Further Reading